# OnCo record inetetamab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/inetetamab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "inetetamab" ;
  schema:name "Inetetamab"@en ;
  schema:alternateName "Cipterbin"@en ;
  schema:description "Inetetamab is 3SBio's HER2 antibody, approved in China in 2020 with vinorelbine for HER2-positive metastatic breast cancer."@en ;
  schema:url <https://onco.cc/drugs/inetetamab/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=inetetamab> ;
  onco:status "approved" ;
  onco:tag "china", "nmpa-approved" ;
  onco:modality "Anti-HER2 monoclonal antibody, Fc-engineered" ;
  onco:approval "CN 2020: HER2-positive metastatic breast cancer after chemotherapy, with vinorelbine" ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:companies <https://onco.cc/companies/3sbio/> ;
  onco:trials <https://onco.cc/trials/nct04736589/>, <https://onco.cc/trials/nct07366840/>, <https://onco.cc/trials/nct04963595/> .